Benefits of Sustained Anti-VEGF Delivery in Wet-AMD


The chief medical officer of Eyevensys discussed the company’s work in developing sustained drug delivery systems.

“We're using electrotransfection to basically induce the ciliary muscle, we're driving plasmids, which have an encoded therapeutic protein on the plasmid, into the ciliary muscle. The ciliary muscle cells will now produce the protein in the eye, and will secrete the protein into the vitreous."

EYS809, a nonviral gene therapy sustained drug-delivery product that delivers anti-vascular endothelial growth factor (VEGF) to the eye, may replace the need for repeated intravitreal injections and improve vision in patients diagnosed with wet age-related macular degeneration (AMD). The investigational therapy from Eyevensys is a dual-gene plasmid designed to deliver sustained concentrations of both the anti-VEGF inhibitor aflibercept (Eylea, Regeneron Pharmaceuticals) and decorin, an endogenous transforming growth factor-beta inhibitor with known anti-angiogenic and anti-fibrotic properties, that has been demonstrated to reduce choroidal neovascularization (CNV) in the rat laser CNV model. 

EYS809 uses electrotransfection to deliver DNA plasmids rather than viral vectors. This approach may be more advantageous as there is no need for subretinal surgery, easy delivery, and no immunogenicity related to the vector. Dosing can be repeated to extend treatment effect and the relatively unlimited cargo capacity allows for the delivery of 2 therapeutic proteins.

GeneTherapyLive spoke with Ronald Buggage, MD, chief medical officer of Eyevensys, to learn more about how sustained drug delivery could help improve patient care in wet-AMD. He also discussed the electrotransfection process of gene delivery.

Related Videos
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
© 2024 MJH Life Sciences

All rights reserved.